What do developments of smart hospitals and smart homes mean for patients, health
professionals and policy makers? Better diagnostics? Better medicines? Greater efficiency?
Nowadays use of the term artificial intelligence (AI) elicits all sorts of reactions, from
enthusiasm to fear. How much are these reactions well-founded? One thing is clear: when it
comes to health, AI can be applied in myriad ways, from all of the departments in a hospital
to all corners of one’s home.
Terms such as smart hospitals and smart homes are frequently used to capture the huge potential in those locations. However, how much evidence is there that all expectations will be met? Moreover, when we assess AI applications in healthcare, should we include other criteria besides health outcomes and healthcare efficiency? For example, it is likely that many people would not desire a smart home that is proven to improve health outcomes if IT sensors in every room were required; for them, privacy overshadows health.
Given the patchy performance of public health approaches during the COVID-19
pandemic, with the benefit of hindsight, how can we better harness available data to improve decision making for improved societal health, cost management, and patient outcomes – better safety of medicines, control of long-term conditions and solutions for rare/orphan diseases?
Chairs: Donald Singer, Ken Redekop
Dirk Smeets, Icometrix
Nigel Hughes, EHDEN
Andrew Fried, former IBM Watson
Richard Barker, New Medicines Partners